PetMed Express (PETS) trims quarterly loss as sales fall 19.9%

Rhea-AI Filing Summary

PetMed Express reported first quarter results for the period ended June 30, 2026. Net sales were $41.0 million, down 19.9% from $51.2 million a year earlier as lower consumer promotional usage was more than offset by weaker prescription medication sales. Net loss was $6.1 million, or $(0.28) per diluted share, a substantial improvement from a $34.2 million loss, or $(1.65) per share, primarily due to the absence of prior-year goodwill and trade name impairment charges and lower general and administrative and advertising expenses, partially offset by lower gross profit.

Adjusted EBITDA was $(3.4) million, compared with $(2.7) million in the prior-year quarter, reflecting a $0.8 million decline. Operating cash use improved but remained negative, with net cash used in operating activities of $7.7 million versus $12.3 million a year earlier. Cash and cash equivalents were $13.1 million at June 30, 2026, down from $21.4 million at March 31, 2026. Management highlighted more efficient marketing with 70,000 new customers and a 15% lower acquisition cost, nearly 14% lower general and administrative expenses, completion of an SAP ERP rollout, and a recently announced sale-leaseback intended to strengthen the balance sheet.

Positive

• Net loss narrowed to $6.1 million from $34.2 million year over year, an 82% improvement primarily driven by the absence of prior-year impairment charges and reduced operating expenses.
• Operating cash outflow improved to $7.7 million from $12.3 million in the prior-year quarter, indicating lower cash burn despite continued losses.
• General and administrative expenses fell by nearly 14%, and customer acquisition cost declined 15% year over year while adding 70,000 new customers, suggesting improving operating efficiency.

Negative

• Net sales declined 19.9% to $41.0 million from $51.2 million in the prior-year quarter, driven by weaker prescription medication sales.
• Adjusted EBITDA deteriorated to $(3.4) million from $(2.7) million, a $0.8 million worsening despite cost reductions.
• Cash and cash equivalents fell to $13.1 million from $21.4 million three months earlier, reflecting ongoing operating and investing cash outflows.

Filing Explained

At June 30, 2026, PetMed Express reported 21,682,381 common shares issued and outstanding, versus 21,385,638 at March 31; this records a changed ownership structure, but the filing does not identify why the count differed.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Net sales: $41.0 million Net loss: $6.1 million Adjusted EBITDA: $(3.4) million +4 more

7 metrics

Net sales $41.0 million Three months ended June 30, 2026; down 19.9% from $51.2 million in 2025

Net loss $6.1 million Three months ended June 30, 2026; improved from $34.2 million in 2025

Adjusted EBITDA $(3.4) million Three months ended June 30, 2026; compared with $(2.7) million in prior-year quarter

Operating cash flow $(7.7) million Net cash used in operating activities for the three months ended June 30, 2026

Cash and cash equivalents $13,079 Balance at June 30, 2026, on the consolidated balance sheet

General and administrative expenses $11,197 Three months ended June 30, 2026; management cites nearly 14% reduction year over year

Basic and diluted net loss per share $(0.28) Three months ended June 30, 2026, based on 21,682,381 weighted-average shares

Key Terms

Adjusted EBITDA, sale-leaseback transaction, SAP ERP system, operating lease right-of-use assets, +2 more

6 terms

Adjusted EBITDA financial

"Adjusted EBITDA1 was $(3.4) million compared to $(2.7) million in the prior year period."

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

sale-leaseback transaction financial

"with our recently announced sale-leaseback transaction, we took an important step toward strengthening our balance sheet"

A sale-leaseback transaction is when a company sells an asset it owns—often real estate or equipment—to a buyer and immediately rents the same asset back so it can keep using it. It matters to investors because it converts a fixed asset into cash while creating a new ongoing rental expense, which can boost short-term liquidity but also change long-term cash flow and debt metrics; think of selling your house and signing a lease to stay as a tenant.

SAP ERP system technical

"completed one of the largest milestones in our technology transformation with the enterprise-wide rollout of our new SAP ERP system"

operating lease right-of-use assets financial

"Operating lease right-of-use assets, net | 395 | | | 512"

An operating lease right-of-use (ROU) asset is an accounting entry that shows the value of a leased item you have the legal right to use—like a building, vehicle, or equipment—recorded on a company’s balance sheet along with the corresponding lease obligation. Investors care because it adds to reported assets and liabilities, changing measures like leverage and return on assets much like bringing a long-term rental onto the company’s financial snapshot, which can affect credit terms and valuation.

share-based compensation financial

"We believe it is useful to exclude non-cash charges, such as share-based compensation expense (benefit)"

Share-based compensation is when a company pays employees, executives or directors with its own stock or rights to buy stock instead of, or in addition to, cash. Think of it like receiving store gift cards instead of extra paycheck — it can motivate staff to boost the company’s value, but it also increases the number of shares outstanding and can shrink each existing owner’s slice of profits and voting power. Investors watch it because it affects reported earnings, share count and the alignment between management and shareholders.

impairment of goodwill and intangible assets financial

"Impairment of goodwill and intangible assets | — | | | 27,258"

An impairment of goodwill and intangible assets occurs when a company determines the value recorded on its books for items like goodwill, brand names, patents, or customer lists is higher than what those assets are actually worth. For investors, impairments matter because they force the company to write down value as an expense, reducing reported profits and shareholders’ equity and signaling that past acquisitions or future earnings expectations may have been overestimated—similar to admitting you paid more for a used car than it’s now worth.

Earnings Snapshot

Net sales: $41.0 million

Three months ended June 30, 2026

Net sales $41.0 million decreased 19.9% from $51.2 million in the prior-year quarter

Net loss $6.1 million improved by $28.0 million from $34.2 million in the prior-year quarter

Adjusted EBITDA $(3.4) million declined by $0.8 million from $(2.7) million in the prior-year quarter

FAQ

How did PetMed Express (PETS) perform financially in the quarter ended June 30, 2026?

PetMed Express reported net sales of $41.0 million and a net loss of $6.1 million for the quarter ended June 30, 2026. Sales declined 19.9% year over year, while the loss improved sharply from $34.2 million a year earlier.

What was PetMed Express (PETS) adjusted EBITDA for the June 30, 2026 quarter?

Adjusted EBITDA for PetMed Express was $(3.4) million for the quarter ended June 30, 2026. This compares with $(2.7) million in the prior-year period, reflecting a $0.8 million decline in this non-GAAP profitability measure.

How did PetMed Express (PETS) revenue change year over year in Q1 2026?

Net sales for PetMed Express were $41.0 million, down from $51.2 million in the prior-year quarter. This represents a 19.9% year-over-year decline, mainly due to reduced prescription medication sales outweighing lower consumer promotional usage.

What is the cash position of PetMed Express (PETS) as of June 30, 2026?

As of June 30, 2026, PetMed Express held $13.1 million in cash and cash equivalents. This was down from $21.4 million at March 31, 2026, after $7.7 million of net cash used in operating activities during the quarter.

How did operating expenses impact PetMed Express (PETS) results in Q1 2026?

Operating expenses totaled $17.6 million, down sharply from $48.5 million a year earlier. The decrease mainly reflects the absence of prior-year impairment charges plus lower general and administrative and advertising expenses, which helped reduce the net loss significantly.

What strategic or operational steps did PetMed Express (PETS) highlight this quarter?

Management highlighted a 15% reduction in customer acquisition cost, acquisition of 70,000 new customers, nearly 14% lower general and administrative expenses, completion of an enterprise-wide SAP ERP rollout, and a sale-leaseback transaction aimed at strengthening the balance sheet.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/13/2026 - 04:18 PM Accepted by SEC EDGAR 08/13/2026 - 04:17 PM Learn about SEC filing dates

0001040130FALSE00010401302026-08-132026-08-130001040130us-gaap:CommonStockMember2026-08-132026-08-130001040130us-gaap:PreferredStockMember2026-08-132026-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 13, 2026

PetMed Express, Inc.

(Exact name of registrant as specified in its charter)

Florida

000-28827

65-0680967

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

420 South Congress Avenue, Delray Beach, Florida 33445

(Address of principal executive offices) (Zip Code)

(561) 526-4444

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $.001 per share			PETS			NASDAQ
Preferred Stock Purchase Rights			N/A			NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2026, PetMed Express, Inc. (the “Company”) issued a press release announcing its June 30, 2026 fourth quarter and fiscal year end financial results and other financial information and announcing that management would review these results in a conference call and webcast at 4:30 pm Eastern time on August 13, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02 and the information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended (“Securities Act”), or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

99.1 – Press release dated August 13, 2026.

104 – Cover Page Interactive Data File (embedded within the Inline XBRL document).

EXHIBIT INDEX

Exhibit No.						Description
99.1						Press release dated August 13, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 13, 2026

			PETMED EXPRESS, INC.
			By:			/s/ Leslie C.G. Campbell
			Name:			Leslie C.G. Campbell
			Title:			Interim Chief Executive Officer and President (principal executive officer)

3

Exhibit 99.1

PetMeds® Announces First Quarter Financial Results

Delray Beach, Florida, August 13, 2026, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2026. 

Quarterly Highlights

•Net sales demonstrated sequential quarterly stabilization. For the first quarter ended June 30, 2026, net sales were $41.0 million compared to $51.2 million for the prior year period, a decrease of 19.9%, as lower consumer promotional usage was more than offset by a decline in prescription medication sales.

•Net loss for the quarter ended June 30, 2026, was $6.1 million, or $(0.28) per diluted share, compared to a net loss of $34.2 million, or $(1.65) per diluted share, for the prior year period. The decrease in net loss was primarily driven by the absence of the prior-year goodwill and trade name impairment charges and to a lesser extent lower general and administrative expenses and advertising expenses. These favorable factors were partially offset by lower gross profit primarily driven by lower manufacturer rebates as a percentage of sales, partially offset by lower net freight costs per order.

•Adjusted EBITDA1 was $(3.4) million compared to $(2.7) million in the prior year period.

“Our first quarter results reflect continued progress toward our goal of establishing a direct, clear path back to sustainable profitability," said Leslie Campbell, Chairman and Interim CEO and President of PetMeds. "We are pleased that net sales have stabilized sequentially over the past several quarters, and we continued to make our marketing spend more efficient, acquiring 70,000 new customers while reducing our cost of acquiring a new customer by 15% year-over-year. At the same time, disciplined expense management drove a nearly 14% reduction in general and administrative expenses. We also completed one of the largest milestones in our technology transformation with the enterprise-wide rollout of our new SAP ERP system, further modernizing and strengthening our financial systems and reporting processes. And with our recently announced sale-leaseback transaction, we took an important step toward strengthening our balance sheet and enhancing our financial flexibility to invest in the initiatives with the greatest potential to drive shareholder returns."

Earnings Webcast

A webcast reviewing financial results for the first quarter fiscal year ended June 30, 2026 is available at the “News & Events” section of the Company’s investor relations website at https://investors.petmeds.com/News--Events/events-and-presentations/default.aspx.

About PetMed Express, Inc.

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PETS family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com

Forward Looking Statement

This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K to be filed for the year ended March 31, 2026. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements,

1 Adjusted EBITDA is a non-GAAP financial measure. See “Non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures.

which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

Investor Contact:

ICR, LLC

Reed Anderson

(646) 277-1260

investor@petmeds.com

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except for share and per share amounts) (Unaudited)

			June 30, 2026						March 31, 2026
			(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents			$	13,079					$	21,412
Accounts receivable, less allowance for credit losses of $0 and $25, respectively			1,706						1,908
Inventories, net			8,468						13,608
Prepaid expenses and other current assets			4,256						6,378
Prepaid income taxes			96						258
Total current assets			27,605						43,564
Noncurrent assets:
Property and equipment, net			25,213						26,326
Intangible and other assets, net			10,549						10,789
Operating lease right-of-use assets, net			395						512
Total noncurrent assets			36,157						37,627
Total assets			$	63,762					$	81,191
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable			$	12,298					$	20,906
Sales tax payable			20,603						22,261
Accrued expenses and other current liabilities			6,654						7,665
Current operating lease liabilities			414						493
Deferred revenue			629						689
Income taxes payable			—						20
Total current liabilities			40,598						52,034
Deferred tax liabilities, net			175						175
Operating lease liabilities, net of current lease liabilities			—						42
Total liabilities			$	40,773					$	52,251
Shareholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized:
Convertible preferred stock, $0.001 par value, with a liquidation preference of $4 per share, 250,000 shares authorized; 2,500 and 2,500 convertible shares issued and outstanding, respectively			9						9
Series A Junior Participating Preferred Stock, $0.001 par value, 100,000 shares authorized; no shares issued or outstanding			—						—
Common stock, $.001 par value, 40,000,000 shares authorized; 21,682,381 and 21,385,638 shares issued and outstanding, respectively			22						21
Additional paid-in capital			19,840						19,647
Retained earnings			3,118						9,263
Total shareholders' equity			22,989						28,940
Total liabilities and shareholders' equity			$	63,762					$	81,191

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF (LOSS) INCOME

(In thousands, except for share and per share amounts) (Unaudited)

									Three Months Ended June 30,
															2026						2025
Net sales															$	41,015					$	51,180
Cost of sales															29,682						36,777
Gross profit															11,333						14,403
Operating expenses:
General and administrative															11,197						12,948
Advertising															4,220						6,046
Depreciation and amortization															2,148						2,283
Impairment of goodwill and intangible assets															—						27,258
Total operating expenses															17,565						48,535
Loss from operations															(6,232)						(34,132)
Other income:
Interest (expense) income, net															(338)						(198)
Other, net															438						187
Total other income (expense)															100						(11)
Loss before provision for income taxes															(6,132)						(34,143)
Provision for income taxes															13						9
Net loss															$	(6,145)					$	(34,152)
Basic and diluted net loss per share															$	(0.28)					$	(1.65)
Basic and diluted weighted-average common shares outstanding															21,682,381						20,755,416

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands) (Unaudited)

			Three Months Ended June 30,
			2026						2025
Cash flows from operating activities:
Net loss			$	(6,145)					$	(34,152)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			2,148						2,283
Impairment of goodwill and intangible assets			—						27,258
Share based compensation			198						591
Bad debt (recovery) expense			—						(6)
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:
Accounts receivable			202						718
Inventories			5,140						(2,156)
Prepaid income taxes			162						—
Prepaid expenses and other current assets			2,122						(1,170)
Operating lease right-of-use assets, net			117						112
Accounts payable			(8,608)						(3,523)
Sales tax payable			(1,658)						127
Accrued expenses and other current liabilities			(1,164)						(1,287)
Lease liabilities			(121)						(113)
Deferred revenue			(60)						(977)
Income taxes payable			(20)						24
Net cash used in operating activities			(7,687)						(12,271)
Cash flows from investing activities:
Purchases of property and equipment			(641)						(1,292)
Net cash used in investing activities			(641)						(1,292)
Cash flows from financing activities:
Dividends paid			—						(1)
Cash paid for tax withholding on net settlement of restricted stock			(5)						(29)
Net cash used in financing activities			(5)						(30)
Net decrease in cash and cash equivalents			(8,333)						(13,593)
Cash and cash equivalents, at beginning of period			21,412						54,720
Cash and cash equivalents, at end of period			$	13,079					$	41,127
Supplemental disclosure of cash flow information:
Cash paid for income taxes net of refunds			$	(120)					$	(4)
Dividends payable in accrued expenses and other current liabilities			$	—					$	23
Non-cash investing activity for property and equipment additions			$	155					$	478

Non-GAAP Financial Measures

To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA, a non-GAAP financial measure that we calculate as net income excluding share-based compensation expense (benefit), depreciation and amortization; income tax provision, interest income (expense), and other non-operational expenses. We have provided reconciliations below of net (loss) income to adjusted EBITDA, the most directly comparable GAAP financial measures.

We have included adjusted EBITDA, herein, because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.

We believe it is useful to exclude non-cash charges, such as share-based compensation expense (benefit) and depreciation and amortization from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe that it is useful to exclude other non-operational expenses, employee severance, impairment of goodwill and intangible assets, and interest expense relating to an estimated unremitted prior sales tax accrual as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a financial measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

•Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;

•Adjusted EBITDA does not reflect net share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;

•Adjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;

•Adjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems;

•Adjusted EBITDA does not reflect certain non-operating expenses including the employee severance which reduces cash available to us;

•Adjusted EBITDA does not reflect certain non-operating expenses (income) including sales tax expense (income) relating to recording a liability for sales tax we did not collect from our customers;

•Other companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces the measures usefulness as comparative measures.

Because of these and other limitations, Adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.

The following table presents a reconciliation of net loss, the most directly comparable GAAP measure to Adjusted EBITDA for each of the periods indicated:

Reconciliation of Unaudited Non-GAAP Measures

PetMed Express, Inc.

			Three Months Ended
($ in thousands, except percentages)			June 30, 2026						June 30, 2025						$ Change						% Change
Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:
Net loss			$	(6,145)					$	(34,152)					$	28,007					82		%
Add (subtract):
Stock-based Compensation			198						591						(393)						(66)		%
Income Taxes			13						9						4						44		%
Depreciation and Amortization			2,148						2,283						(135)						(6)		%
Interest Expense (Income), Net			338						198						140						71		%
Employee Severance			—						95						(95)						n/m
Professional Fees (1)			—						1,021						(1,021)						n/m
Impairment of goodwill and intangible assets			—						27,258						(27,258)						n/m
Adjusted EBITDA			$	(3,448)					$	(2,697)					$	(751)					28		%

(1) Consists of professional fees related to the investigation as previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2025.

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EX-99.1 157.3 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2.1 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT 15.6 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 27.3 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 16.3 KB